Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study GroupWolfgang R. Sperr, Peter Valent, Friedrich Wimazal et al.|Annals of Oncology|2009Cited by 117
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blastsGuillermo Garcia‐Manero, Oliver G. Ottmann, Mikkael A. Sekeres et al.|Leukemia|2017Cited by 70
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Richard Greil, Arlene S. Swern et al.|International Journal of Molecular Sciences|2017Cited by 51